Clinical trial
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous…
NCT00321581 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00321581 |
|---|---|
| Title | AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia |
| Official title | Phase I Trial of CEDIRANIB (AZD2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory or Recurrent Solid Tumors, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Cediranib, AZD2171, RECENTIN |
| Enrollment | 18 |
| Start date | May 1, 2006 |
| Completion | Oct 6, 2011 |
| First posted | May 4, 2006 |
| Last update posted | Nov 21, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: